Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases

确定阿尔茨海默病和其他神经退行性疾病的新免疫调节靶点

基本信息

批准号：
9766179
负责人：
Benjamin Jacob Doranz
金额：
$ 20.38万
依托单位：
INTEGRAL MOLECULAR
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-01 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9766179
关键词：
Abbreviations Alzheimer&apos s Disease American Antibodies Area Astrocytes Binding Biosensor Cause of Death Cells Clinical Trials Communication Disease Disease Progression Generations Genetic Goals Health Human Immune Immunooncology Intervention Ligands Link Membrane Membrane Proteins Microglia Molecular Molecular Conformation Neurodegenerative Disorders Neurofibrillary Tangles Neuroimmune Pathologic Pharmaceutical Preparations Phenotype Prevalence Process Proteins Proteome Receptor Cell Risk Senile Plaques Specificity Structure Surface T-Lymphocyte Technology Testing Therapeutic Therapeutic Clinical Trial TimeLine Titrations Treatment Efficacy Virus Receptors Work cell type disability effective therapy experimental study genome wide association study immune checkpoint immunoregulation neuroregulation new therapeutic target novel oncology prevent receptor response risk minimization screening tau Proteins therapeutic target therapy development

项目摘要

ABSTRACT Alzheimer's disease (AD) and other neurodegenerative diseases are a major cause of death and disability for older Americans, with a US prevalence of more than 6.5 million. As AD currently cannot be cured or prevented, there is an urgent need for effective treatments targeting underlying disease processes. A major roadblock in treatment development has been the lack of good targets. Although pathologically important, amyloid beta plaques and tau tangles are not easily druggable, and clinical trials of therapeutics targeting these proteins directly have largely failed. Recent genome-wide association studies have identified a link between a growing number of modulatory proteins on neuroimmune cells, particularly on the surface of microglia and astrocytes, that are linked to the risk of developing AD. The identification of new proteins with neuroimmunomodulatory activities could enable an entirely new generation of therapeutic targets with the potential to treat, delay, and possibly even prevent AD and other neurodegenerative diseases.

抽象的阿尔茨海默氏病（AD）和其他神经退行性疾病是主要的死亡原因美国年龄较大的美国人的残疾，美国患病率超过650万。作为广告目前无法治愈或预防，迫切需要有效治疗针对潜在的疾病过程。治疗开发的主要障碍已经缺乏良好的目标。尽管在病理上很重要，但淀粉样蛋白β斑块和tau 缠结不容易吸毒，并且针对这些蛋白质的治疗疗法的临床试验直接失败了。最近的全基因组关联研究已经确定了一个联系在神经免疫细胞上越来越多的调节蛋白之间，尤其是在小胶质细胞和星形胶质细胞的表面与发展AD的风险有关。这通过神经免疫调节活动鉴定新蛋白质可以完全启用新一代的治疗靶标有可能治疗，延迟甚至可能预防AD和其他神经退行性疾病。